Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

iShares Biotechnology ETF (NQ:IBB)

142.60 +1.60 (+1.13%)
Streaming Delayed Price Updated: 12:33 PM EDT, Sep 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about iShares Biotechnology ETF

Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
The Federal Reserve's recent 50bps rate cut could significantly boost biotech companies by lowering borrowing costs and improving access to capital. 
Via MarketBeat
Topics ETFs Economy
Biotech Breakout: Stocks for Your Watchlist
The iShares Biotechnology ETF (IBB) has turned $140 resistance into support, positioning the overall sector for a potential breakout above $150. 
Via MarketBeat
Topics ETFs
CPI Data Sparks Rally in Biotech Stocks
Following lower-than-expected inflation data on Thursday, The biotech sector broke out above resistance, closing the week up 6%, far outperforming the market. 
Via MarketBeat
Topics ETFs Economy
AbbVie Stock: A Perfect Dip for Investors to Buy
ABBV stock is down over 3% to start the second half of the year; the stock may be overvalued in the short term but still offers value for long-term investors 
Via MarketBeat
Topics ETFs
Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
The biotech sector (IBB) is trading just 3% away from its 52-week high and a significant resistance level, suggesting a potential breakout. 
Via MarketBeat
Topics ETFs
Gilead Sciences Stock Surges on HIV Treatment Trial Success
Gilead Sciences (NASDAQ: GILD) saw its stock jump nearly 10% yesterday after announcing groundbreaking results from its HIV treatment trial. 
Via MarketBeat
Will the Biotech Sector Shift From Lagger to Leader?
The biotech sector has experienced a significant rally after bouncing off uptrend support and is now consolidating near major SMAs. 
Via MarketBeat
Topics ETFs
Biotech Sector Nears Breakout: Will it Outperform in Q2?
The Biotech sector ETF is consolidating in its upper range, indicating a potential sector breakout despite modest year-to-date gains 
Via MarketBeat
Topics ETFs
Will the Biotech sector sustain its momentum in 2024?
The iShares Biotechnology ETF (NASDAQ: IBB) emerged as a standout star, closing the first day of the year with a solid upswing of nearly 4%. 
Via MarketBeat
Topics ETFs
MarketBeat Week in Review – 12/4 - 12/8
Stocks finished in the green to close the week; investors believe the jobs report will allow the Fed to leave interest rates unchanged when they meet next week 
Via MarketBeat
Topics Economy
3 biotech powerhouses poised to thrive amid sector rebound
If the newfound support and uptrend in the biotech sector last, as the new year quickly approaches, the biotech sector could shift from lagger to leader. 
Via MarketBeat
Topics ETFs
Biotech reversal confirmed: what's ahead for the IBB?
The recent reversal and reclaim of the significant $124 support level in the IBB holds importance, indicating a potential shift in momentum. 
Via MarketBeat
Topics ETFs
3 Strong Biotech Performers To Watch As Sector Nears Breakout
As the IBB ETF nears a potential breakout, watch for strong performers like Regeneron Pharmaceuticals, Vertex, and Exelixis to continue outperforming. 
Via MarketBeat
Topics ETFs
Moderna: Declining Performance And Relative Weakness
Moderna's value has declined by over 75% from its peak as the world moves on from the COVID-19 pandemic, leading to concerns about its investment appeal. 
Via MarketBeat
Topics ETFs
Is the Biotech Industry (IBB) Poised For A Major Breakout?
The current consolidation in the IBB signals a potential breakout might be looming as key moving averages have converged within a contracted price range. 
Via MarketBeat
Topics ETFs
Tarsus Added to NASDAQ Biotechnology Index
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
BriaCell’s Lead Candidate Bria-IMT™ Shows Promising Results For Advanced Breast Cancer Patients
The world of biotech is having what some are calling a golden age. Many companies are presenting new and innovative drugs to the FDA for approval and later the public for consumption. Smart Beta EFTs... 
Via TheNewswire.com
Topics Stocks
BlackRock Announces Product Updates to Two iShares ETFs
From BlackRock, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.